Journal
ONCOIMMUNOLOGY
Volume 1, Issue 7, Pages 1181-1182Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.20639
Keywords
T-reg cells; immunotherapy; interleukin-2; tumor
Categories
Ask authors/readers for more resources
Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available